Previous 10 |
home / stock / wxxwy / wxxwy news
SHANGHAI and NEW YORK , April 3, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has received the 2019 C...
SHANGHAI and SINGAPORE , March 26, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (Stock Code: 2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has recei...
WuXi Biologics to be the first biologics company in China approved by both the U.S. FDA and EMA SHANGHAI and WUXI, China , March 20, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end...
HONG KONG , March 18, 2019 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ( " WuXi Biologics " or " the Group ", stock code: 2269.HK) , a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, deve...
- The second product successfully receiving Breakthrough Therapy Designation that WuXi Biologics has enabled its partner to develop SHANGHAI , Feb. 28, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (Stock code: 2269.HK), a leading global open-access biologics technology...
SHANGHAI and SEOUL , Feb. 26, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and ABL Bio Corporation ("ABL Bio") (29...
WuXi Biologics completed EMA GMP Inspection, the first biologics company in China SHANGHAI , Feb. 19, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics disco...
SHANGHAI , Feb. 19, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that the European Medicines Agency (EMA)...
SHANGHAI and CRANBURY, N.J. , Feb. 12, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Amicus Therapeutics ("Amicus...
News, Short Squeeze, Breakout and More Instantly...
Wuxi Biologics Cayman Inc ADR Company Name:
WXXWY Stock Symbol:
OTCMKTS Market:
Amid the ongoing scrutiny from Congress, WuXi AppTec and its affiliates face another setback as the Biotechnology Innovation Organization...
SHANGHAI, Jan. 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufa...
WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale PR Newswire By leveraging WuXiUP TM , WuXi Biologics has completed its first end-to-end continuous drug substance (DS) manufacturing ...